Evogene (EVGN) Net Cash Flow (2013 - 2026)
Evogene (EVGN) posted Net Cash Flow of -$4.4 million for Q1 2026, down 160.74% sequentially from $7.3 million in Q4 2025, and up 42.88% YoY from -$3.1 million in Q1 2025.
Evogene (EVGN) Net Cash Flow (2013 - 2026) Analysis & Trends
Evogene has reported Net Cash Flow for 14 years, with the latest figure at -$4.4 million in Q1 2026.
- Quarterly Net Cash Flow rose 42.88% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.7 million (down 246.38% YoY) and the FY2025 annual result came in at -$2.4 million, up 56.36% from the prior year.
- Net Cash Flow retreated to -$4.4 million in Q1 2026 per EVGN's latest filing, from $7.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $19.6 million in Q1 2022 and troughed at -$10.3 million in Q3 2025.
- A 5-year average of $2.5 million and a median of $3.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 381.33% in 2022, then plunged 1157.84% in 2025.
- Over 5 years, Net Cash Flow stood at -$3.1 million in 2022, then soared by 269.67% to $5.2 million in 2023, then declined by 23.13% to $4.0 million in 2024, then surged by 83.44% to $7.3 million in 2025, then tumbled by 160.74% to -$4.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$4.4 million, $7.3 million, and -$10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | 7.32 Mn |
| Dec 31, 2025 | 7.32 Mn |
| Sep 30, 2025 | -10.34 Mn |
| Sep 30, 2025 | -10.34 Mn |
| Jun 30, 2025 | -3.29 Mn |
| Jun 30, 2025 | -3.29 Mn |
| Mar 31, 2025 | -7.79 Mn |
| Mar 31, 2025 | -7.79 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 8.67 Mn |
| Jun 30, 2024 | 8.67 Mn |
| Mar 31, 2024 | -619,000.00 |
| Mar 31, 2024 | -619,000.00 |
| Dec 31, 2023 | 5.19 Mn |
| Dec 31, 2023 | 5.19 Mn |